Phesi releases 2023 analysis of clinical development; breast cancer remains most studied disease area for third year

Date: 01. 16. 2024

Annual analysis of data from 95 million patients shows signs of post-pandemic recovery for clinical development industry, but trial cancellation rates at Phase II remain high

Boston, USA, January 16 2024: Phesi, a global provider of patient-centric data analytics, has today released the results of its annual global analysis of all clinical trials conducted in 2023, using data from its Trial Accelerator™ platform. The analysis of 65,749 recruiting clinical trials reveals that breast cancer is the most studied disease for the third consecutive year, followed by solid tumours (Fig. 1). The top five most studied disease areas with the most recruiting sites have stayed the same for two consecutive years, but in 2023, the ranking of disease areas has changed. This year, stroke was the third most studied disease area, Covid-19 was fourth and prostate cancer was fifth. Phesi’s analysis also revealed that the US is home to 33% of the 115,000 recruiting investigator sites from interventional trials around the world – with as many sites as the next top seven countries combined. 

“The positive news is there has been an increase in trial recruitment across all the top five indications in 2023. What has been especially notable is the increase in solid tumor trials – these are likely to be the foundation of innovative cancer therapies, and investment in this area is a promising sign for patients,” explained Dr Gen Li, President, Phesi. “Meanwhile, we have seen a marked reduction in investment into Covid-19 therapies in 2023, likely due to there being fewer available patients. The prospective market for Covid therapies is less attractive for investment, and we expect to see this downward trend to continue.”

The analysis also revealed that the increased attrition rate at Phase II identified by Phesi’s analysis in 2022 persists (Fig. 2). In 2023, 28% of clinical trials were cancelled during Phase II – a rate that averaged around 20% before the pandemic. These high levels of attrition at Phase II may slow the rate at which new therapies reach market and are likely to have an ongoing effect on the clinical development industry, adding to rising costs. Moreover, it is likely that Phase III cancellations will rise in the coming years; trials that struggled to meet goals during Phase II have a higher likelihood of not reaching the end of Phase III successfully.

Dr Zhen Su, CEO of Marengo Therapeutics  and Former Global Franchise Head of Oncology at Merck KGaA commented, “Science & technology are transforming cancer care, and promising next wave novel therapeutics offer much hope for patients. Marengo’s mission – enabling the activation of patients’ immune cells to protect against cancer – relies upon in-depth research to uncover the most appropriate immune cells to target cancer. It’s encouraging to see this latest analysis from Phesi, which underlines that research into cancer and solid tumors continues to be major priority for the clinical development industry. We hope this increased investment and enthusiasm will aid Marengo’s mission and the cancer patients we seek to help.” 

“While there was a slight improvement in cancellation rates in the second half of the year, the data indicate that 2024 will pose further challenges to portfolio managers and trial planners. Ultimately, the clinical development industry is beginning to recover from the pandemic, but we can expect the long-term impact to stretch into 2025,” commented Dr Li. “To minimize the impact of disruption, there is a growing need for trial design and execution to become more data-led. Using predictive analytics in protocol design, simulating trials, and using digital patient profiles will reduce unnecessary amendments, accelerate development and importantly, get therapies to patients faster.”

Phesi uses the world’s largest clinical trial database to simulate clinical development and improve decision making. With AI-driven solutions for patient profiling, trial simulation, protocol design and digital control arms available to support life sciences companies in accelerating drug development and commercialization. Find out more about Phesi and the Phesi Trial Accelerator™ platform.

For the full report with 2023 analysis, visit: https://info.phesi.com/2024-most-studied.

 

 

 

 

 

Figure 1. The top five most studied disease indications in 2023 

 Figure 2. Phase II attrition rate (2016-2023)

Related news
02. 12. 2024
Phesi announces AI-driven Trial Accelerator™ hits critical milestone with data from 100 million patients Read more
10. 15. 2023
Phesi launches Health Check and Trial Rescue Service to save at-risk trials and bring drugs to market faster Read more
09. 07. 2023
Phesi and Krystelis collaborate to launch new Diversity, Equity, and Inclusion Data Service for clinical development Read more
07. 14. 2023
Depression now one of the top five most studied disease areas in clinical development, finds new Phesi global analysis Read more
01. 16. 2023
New Phesi global analysis sees breast cancer retain position as most studied disease area in 2022 Read more
11. 30. 2022
Number of collagen clinical trials more than doubled since 2010, Phesi analysis shows Read more